Spots Global Cancer Trial Database for A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
Official Title: A Phase 1b, Open-Label, Dose-Escalation Study for the Safety, Tolerability, and Pharmacokinetics of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
Study ID: NCT03314922
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of parsaclisib in the treatment of Japanese participants diagnosed with previously-treated B-cell lymphoma.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Aichi Cancer Center Hospital, Aichi, , Japan
National Hospital Organization Kyushu Cancer Center, Fukuoka, , Japan
Cancer Institute Hospital of Jfcr, Koto-ku, , Japan
Nagoya City University Hospital, Nagoya, , Japan
Tohoku University Hospital, Sendai-shi, , Japan
National Cancer Center Hospital, Tokyo, , Japan
Contact Details
Name: Cinthya Coronado, MD
Affiliation: Incyte Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
